Perez-ValeroI, BayonC, CambonI, GonzalezA, ArribasJ. Protease inhibitor monotherapy and the CNS: peace of mind?J Antimicrob Chemother2011;66:1954–62
2.
YilmazA, IzadkhashtiA, PriceR, Darunavir concentrations in cerebrospinal fluid and blood in HIV-1 infected adults. AIDS Res Hum Retroviruses2009;25:1–5
3.
KatlamaC, ValentinMA, Algarte-GeninM, Efficacy of darunavir/ritonavir as single-drug maintenance therapy in patients with HIV-1 viral suppression: a randomized open-label non-inferiority trial, MONOI-ANRS 136. AIDS2010;24:2365–74
4.
ClumeckN, RiegerA, BanhegyiD, 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. J Antimicrob Chemother2011;66:1878–85
5.
CellaDF, McCainNL, PetermanAH, MoF, WolenD. Development and validation of the functional assessment of human immunodeficiency virus infection (FAHI) quality of life instrument. Qual Life Res1996;5:450–63
6.
UK Medical Research Council. A randomised controlled trial of a strategy of switching to boosted protease inhibitor monotherapy versus continuing combination antiretroviral therapy for the long-term management of HIV-1 infected patients who have achieved sustained virological suppression on highly-active antiretroviral therapy C PIVOT trial [online]. See http://www.controlled-trials.com/ISRCTN04857074 (last checked 13 May 2011)
